



Developmental Biology
Regenerative Medicine & Surgery
Pasadena Guild Endowment



David Warburton OBE, DSc, MD, MMM, FRCP, FRCS, FRCPCH, FAAAS, ATSF
Professor of Pediatrics, Surgery & Craniofacial Molecular Biology
Director, Developmental Biology and Regenerative Medicine Program
Director, California Institute of Regenerative Medicine Training Program
and Stem Cell Core Facilities
Director, Fogarty/NIEHS Lifespan Environmental Pollution Global Impact Center
The Saban Research Institute
Children's Hospital Los Angeles
University of Southern California
Keck School of Medicine and Ostrow School of Dentistry

Prof Andreas Fouras,
4Dx
468 St Kilda Rd
Melbourne, Australia

CC: Frontier Health and Medical Research Program Manager
AusIndustry
Department of Industry, Innovation and Science
GPO Box 2013

February 21, 2019

LETTER OF SUPPORT FOR MEDICAL RESEARCH FUTURE FUND FRONTIER HEALTH AND MEDICAL RESEARCH PROGRAM:

4D FUNCTIONAL DIAGNOSIS: A NEW FRONTIER IN LUNG HEALTH FOR CHILDREN

Dear Andreas,

As a research leader in children's health care I have been pleased to collaborate with you, initially as an academic and now as CEO of 4Dx for over four years. I have been particularly interested in how your imaging technology could further both clinical research and practice in all patients, but especially for children. Therefore, it was with great interest that I learned of your game-changing plans to develop the next generation of medical scanner delivering little to no radiation dose, while also providing incredibly rich and detailed lung function data. This is a crucially important project as medical science is held back by our lack of understanding of what is happening inside

the human lungs, especially in sick children. This is amplified by the real risk associated with the radiation cost of existing technology.

The project as we discussed it will cover the needs of all clinical segments of the pulmonary disease diagnosis as well as the evaluation of therapeutic efficacy. As I understand, the Stage1 of this project involves the one-year development of a detailed plan to be executed over five years of Stage2. I'm pleased to serve as an advisor on Stage 1, and to offer the full capabilities of my group to drive laboratory and clinical studies in Stage2.

The Stage1 role involving the advisory activity, will allow me to provide the clinical expertise on the early stage development of this novel human scanner with 4DXV capability. I will strive to assist you to develop the technology in a way that has the maximum positive impact on both research capability as well as clinical practice. I will also work with you and the other project partners on the design of the detailed project plan for stage 2, via expert advice in areas of clinical test development and pulmonary disease diagnosis.

I'm committed to support your initiative in Stage2 of this activity, which will allow us to expand this innovative work into extensive testing and validation. Children's Hospital Los Angeles is consistently ranked in the US News and World Report's top ten of paediatric hospitals. CHLA is eighth among U.S. pediatric hospitals in procuring National Institute of Health (NIH) grant funding. By conducting these studies at CHLA, we can provide vital scientific data, but also expose the technology to the US's population of opinion leading doctors and scientists trial, therefore accelerating the expansion from Australia to the rest of the world.

I look forward to working with you to greatly accelerate progress in lung health for children.

Sincerely,

Yours Sincerely,



David Warburton

Mail: Children's Hospital Los Angeles
4650 W# Sunset Blvd, MS 35
Los Angeles, CA 90027
Telephone: 323 361 5422 (assistant)
Fax: 323 361 3613
Email: dwarburton@chla.usc.edu